Doug Mitchell's lasso peptide research leads to new company, Lassogen

Date

11/05/20
Photo by Julia Pollack

By Alisa King, Institute for Genomic Biology


Although small molecule drugs and antibodies continue to be the standard for cancer treatment, a new class of therapeutics — lasso peptides — may prove effective, especially for disease targets that thwart traditional approaches. Combining the power of antibodies and small molecule drugs, the San Diego-based startup Lassogen is developing lasso peptides as a new therapeutic modality.

Now, with $4.5 million raised in a seed round, the company moves one step closer to demonstrating the power of lasso peptides for treating human diseases such as cancer and autoimmune disorders. 

Lassogen was founded by CEO Mark Burk, PhD, along with co-founder Kent Boles, PhD, and academic co-founders and advisors, Tracy Handel, professor of Pharmaceutical Science at the University of California San Diego and Douglas Mitchell, the John and Margaret Witt Professor of Chemistry at the University of Illinois Urbana-Champaign and a professor at the Carl R. Woese Institute for Genomic Biology  

“For a long time, people have been interested in cyclic peptides as therapeutics as there are certain things you can’t do very well with standard classic molecule drugs,” Mitchell said. “My group here at Illinois was looking at a very unusual class of macrocyclic peptides called lasso peptides. I presented our work at some conferences and this initiated discussions with Mark, after which our relationship was formalized.”

Lasso peptides, as the name suggests, form unique structures that resemble a lasso, rendering them completely heat and protease stable. Their shape and volume also allow them to easily engage the binding pockets of important receptors, overcoming many of the limitations presented by antibodies and small molecule drugs. 

“Lasso peptides are sort of in this Goldilocks zone where they're not too big or too small,” Mitchell said. “They are also globular, unlike most other cyclic peptides. Further, you can boil a lasso peptide and they retain their biological activity and chemical structure. This stability and rigidity have big implications for how they can function in the body.”

In order to find lasso peptides in nature, Mitchell recruited University of Illinois undergraduates to write a discovery algorithm that allowed them to define and catalog lasso peptides found in microbial genomes. Although restrictive to archaea and bacteria, lasso peptides were found to be common and fairly distributed within those domains. What was once a bottleneck is no longer the case, as nearly 5,000 lasso peptides have been discovered.  

With a total of $5.1 million raised since 2019, Lassogen plans to focus its efforts in immuno-oncology, including development of agonists or dual antagonists of cell surface receptors called GCPRs.

“Lassogen has strategically targeted GPCRs that are not exploited medicinally by other therapeutic modalities,” Mitchell said. “There are G protein-coupled receptors that are involved in various types of cancer where there is good validation that modulation of that target could be beneficial for stopping tumor growth or enabling the immune response to eliminate the tumor. We have lasso peptide-based compounds that modulate these targets, and we are exploring ways to exploit the vast potential of lasso peptides in cancer.” 

Lassogen also has a federally funded collaborative project with Mitchell at Illinois to develop a production strategy that would allow enzymatic creation of any desired lasso peptide. Their strategy would allow programming of a substrate to become compatible with an enzyme that would normally not process it, thus enabling discovery and optimization for anticancer research or other therapeutic areas.

“Lasso peptides have solved a paradox where pathways are selective and promiscuous at the same time,” said Mitchell. “You can retain the part that endows selectivity, but then stick something on the other half of the peptide that is unnatural or natural to make these huge combinatorial libraries that select for the activities that you want.” 

As an academic collaborator and consultant, Mitchell will continue working with Lassogen in exploring and honing the chimeric strategy. In addition, some applications are currently underway to work on coronaviruses, where protein-protein interactions are key. 

“The things that we develop and learn in my lab have value to Lassogen and there are specific larger projects that we want to do together,” said Mitchell. “These compounds are underexploited and underleveraged, and in my opinion, too interesting to not pursue.”

 

Related People

douglasm

Directory

scheelinAlexander
Scheeline
bjmccallBenjamin
McCall
r-gennisRobert
Gennis
j-gerltJohn
Gerlt
sgranickSteve
Granick
mgruebelMartin
Gruebele
hergenroPaul
Hergenrother
huangRaven
Huang
mlkraftMary
Kraft
leckbandDeborah
Leckband
yi-luYi
Lu
martinisSusan
Martinis
snairSatish
Nair
eoldfielEric
Oldfield
cmsCharles
Schroeder
zanZaida
Luthey-Schulten
selvinPaul
Selvin
sksScott
Silverman
s-sligarStephen
Sligar
tajkhorsEmad
Tajkhorshid
zhao5Huimin
Zhao
pbraunPaul
Braun
mdburkeMartin
Burke
jeffchanJefferson
Chan
sdenmarkScott
Denmark
dlottDana
Dlott
foutAlison
Fout
agewirthAndrew
Gewirth
ggirolamGregory
Girolami
sohirataSo
Hirata
jainPrashant
Jain
jkatzeneJohn
Katzenellenbogen
nmakriNancy
Makri
douglasmDouglas
Mitchell
jsmooreJeffrey
Moore
murphycjCatherine
Murphy
r-nuzzoRalph
Nuzzo
dimerPhilip
Phillips
rauchfuzThomas
Rauchfuss
joaquinrJoaquín
Rodríguez-López
sarlahDavid
Sarlah
kschweizKenneth
Schweizer
jsweedleJonathan
Sweedler
vddonkWilfred
van der Donk
renskeRenske
van der Veen
vuraweisJosh
Vura-Weis
mcwhite7M.
White
sczimmerSteven
Zimmerman
beakPeter
Beak
wklemperWalter
Klemperer
jdmcdonaJ.
McDonald
pogoreloTaras
Pogorelov
mshen233Mei
Shen
dewoonDavid
Woon
wboulangWilliam
Boulanger
rxbRohit
Bhargava
qchen20Qian
Chen
jianjuncJianjun
Cheng
hy66Hong
Yang
andinomaJosé
Andino Martinez
decosteDonald
DeCoste
thhuangTina
Huang
tjhummelThomas
Hummel
dkellDavid
Kell
doctorkMichael
Koerner
marvilleKelly
Marville
crrayChristian
Ray
tlbrownTheodore
Brown
rmcoatesRobert
Coates
thdjrThom
Dunning
dykstraClifford
Dykstra
j-jonasJiri
Jonas
j-lisyJames
Lisy
shapleyJohn
Shapley
pshapleyPatricia
Shapley
zumdahl2Steven
Zumdahl
ksuslickKenneth
Suslick
jcoxJenny
Cox
sqdSean
Drummond
sheeleySarah
Sheeley
jsmaddenJoseph
Madden
cknight4Connie
Knight
schulzeHeather
Schulze
kbaumgarKeena
Finney
adkssnBeatrice
Adkisson
trabari1Katie
Trabaris
metclfKara
Metcalf
ljohnso2Lori
Johnson
lchenoweLeslie
Chenoweth
wdedoWolali
Dedo
spinnerDavid
Spinner
plblumPatricia
Simpson
stevens2Chad
Stevens
lsagekarLori
Sage-Karlson
bertholdDeborah
Berthold
kecarlsoKathryn
Carlson
sdesmondSerenity
Desmond
axelson2Jordan
Axelson
scbakerStephanie
Baker
pflotschPriscila
Falagan Lotsch
dgrayDanielle
Gray
thennes2Tom
Hennessey
holdaNancy
Holda
aibarrAlejandro
Ibarra
kimshSung Hoon
Kim
kocherg2Nikolai
Kocherginsky
philipk2Philip
Kocheril
legare2Stephanie
Legare
alewandoAgnieszka
Lewandowska
smccombiStuart
McCombie
jdm5Justin
McGlauchlen
egmooreEdwin
Moore
myerscouKathleen
Myerscough
snalla2Siva
Nalla
romanovaElena
Romanova
roubakhiStanislav
Rubakhin
shvedalxAlexander
Shved
asoudaAlexander
Soudakov
xywangXiying
Wang
kwilhelKaren
Wilhelmsen
wilkeyRandy
Wilkey
silongSilong
Zhang
schlembaMary
Schlembach
trimmellAshley
Trimmell
emccarr2Elise
McCarren
cmercierChristen
Mercier
atimpermAaron
Timperman
niesShuming
Nie
hshanHee-Sun
Han
mmgMutha
Gunasekera
kknightsKatriena
Knights
lisawLisa
Williamson
keinckKatie
Einck
kneef1Kate
Neef
txiang4Tiange
Xiang
j-hummelJohn
Hummel
i-paulIain
Paul
munjanjaLloyd
Munjanja
glnGayle
Nelsen
agerardAnna
Gerard
powerskaKimberly
Powers
lolshansLisa
Olshansky
miricaLiviu
Mirica
qingcao2Qing
Cao
lisa3Lisa
Johnson
tinalambTina
Lamb
baronpBaron
Peters
bransle2Sarah
Bransley
dylanmh2Dylan
Hamilton
raegansRaegan
Smith
apm8Angad
Mehta
leverittJohn
Leveritt
xingwXing
Wang
emillrEva
Miller
jmill24Jacqueline
Miller
jlbass2Julia
Bass
ramonarRamona
Rudzinski
tlcraneTracy
Crane
cejohnstCelia
Johnston
adlAmber
LaBau
cnsolomoCandice
Solomon-Strutz
mikaelbMikael
Backlund
jacksonnNick
Jackson